Presence of PCR artifacts in Sanger sequencing in Formalin-fixed paraffin-embedded (FFPE) tissue â€“ experience in a collective of 990 advanced NSCLC
Background: Despite the rapid development of new molecular techniques such as Next Generation Sequencing (NGS), Sanger sequencing has been thus far the gold standard for mutation analysis. It is constantly used for daily routine diagnostics because it represents a quick and comprehensive available method for mutation analyses. Although Sanger sequencing is a good validated method, PCR artifacts may occur in formalin fixed paraffin embedded (FFPE) material. This constitutes a serious source of error.
Aims: To assess the prevalence of typical and atypical EGFR mutations in exon 19 and 21 in a collective of 990 advanced non-small cell lung cancer (NSCLC) patients, focusing especially on methodological issues and challenges concerning mutation analysis, particularly PCR artifacts.
Material and Methods: We examined 990 NSCLC (FFPE material) by Sanger sequencing for exon 19 and 21 of the EGFR gene. Four cases dropped out because of insufficient DNA quality (n =986). Results: Beside 101 typical exon 19 and 21 mutations (99 cases, two double mutations) we found 45 additional cases with distinct peaks at atypical positions in exon 19 and 21 in our first analysis. This would have implied a mutation rate of 14.6 %. Only six of these putative atypical mutations (all exon 21 and none of the exon 19 mutations) could be validated by repeated mutation analysis. All other peaks were not reproducible, therefore considered as PCR artifacts and consequently as wild type. Altogether we found 105 cases (107 mutations, 10.6 % of cases) with typical/atypical mutations in exon 19 and 21 of the EGFR gene.
Conclusion: In our opinion it is in general important to detect and report all mutations even at atypical sites to discover their possible clinical relevance. However, one must always be aware of the possibility, reasons and prevention of PCR artifacts in FFPE tissue. Therefore, prior to reporting mutations at uncommon sites these must be validated by repeated analyses.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
4. In case of virtual slide publication the authors agree to copy the article in a structural modified version to the journal's VS archive.